Medicines in this atlas
The drugs and medicine products this atlas holds that a registry trial names or that carry a regulatory decision, with how many of each. A trial counts for a medicine when its registry record names the medicine under a name this atlas holds for it, so the table does not list every medicine used in these conditions. (page 2 of 4)
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- PCSK9 inhibitors
- Trials
- 47
- Phase 3 or 4
- 38
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 17
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 7
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 42
- Phase 3 or 4
- 37
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 19
-
- Type
- Drug
- Class
- Trials
- 8
- Phase 3 or 4
- 8
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 8
Fibrinolytic (clot-dissolving) drugs
- Type
- Drug
- Class
- Trials
- 32
- Phase 3 or 4
- 26
- Recruiting
- 16
- Regulatory decisions
- 0
- Sponsors
- 22
-
- Type
- Drug
- Class
- Mineralocorticoid receptor antagonists (drug class)
- Trials
- 26
- Phase 3 or 4
- 22
- Recruiting
- 11
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 1
- Regulatory decisions
- 4
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
GLP-1 receptor agonists (drug class)
- Type
- Drug
- Class
- Trials
- 72
- Phase 3 or 4
- 57
- Recruiting
- 12
- Regulatory decisions
- 0
- Sponsors
- 33
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Heparins and low-molecular-weight heparins
- Trials
- 16
- Phase 3 or 4
- 16
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 15
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
Heparins and low-molecular-weight heparins
- Type
- Drug
- Class
- Anticoagulants
- Trials
- 13
- Phase 3 or 4
- 11
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Drug
- Class
- Thiazide and thiazide-like diuretics
- Trials
- 16
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 14
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Drug
- Class
- Omega-3 fatty acid drugs
- Trials
- 4
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 4
-
- Type
- Drug
- Class
- Trials
- 26
- Phase 3 or 4
- 22
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 1
-
- Type
- Drug
- Class
- Thiazide and thiazide-like diuretics
- Trials
- 3
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 3
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 7
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Drug
- Class
- ACE inhibitors
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 6
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 21
- Phase 3 or 4
- 14
- Recruiting
- 2
- Regulatory decisions
- 0
- Sponsors
- 19
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Drug
- Class
- Trials
- 7
- Phase 3 or 4
- 6
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 4
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 11
- Phase 3 or 4
- 9
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 11
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 2
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Inotropes and vasopressors
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 1
Mineralocorticoid receptor antagonists (drug class)
- Type
- Drug
- Class
- Trials
- 19
- Phase 3 or 4
- 16
- Recruiting
- 6
- Regulatory decisions
- 0
- Sponsors
- 9
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 9
- Phase 3 or 4
- 9
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 7
-
- Type
- Drug
- Class
- Inotropes and vasopressors
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 1
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0